BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT00039156

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00039156. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open Phase II Multi-Center Trial of BAY 59-8862 in Patients With Aggressive Refractory Non-Hodgkin's Lymphoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have refractory non-Hodgkin's lymphoma.

Study identification

NCT ID: NCT00039156
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Theradex; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Lymphoma

Interventions

ortataxel Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2002 (Type not available)
Primary completion: Not listed
Completion: Not listed
Last update posted: Jul 24, 2008

Started 2002

United States locations

U.S. sites: 13
U.S. states: 8
U.S. cities: 12

Facility	City	State	ZIP	Site status
Mount Sinai Comprehensive Cancer Center	Miami Beach	Florida	33140	—
University of Chicago Cancer Research Center	Chicago	Illinois	60637-1470	—
Veterans Affairs Medical Center - Shreveport	Shreveport	Louisiana	71101	—
Louisiana State University Health Sciences Center - Shreveport	Shreveport	Louisiana	71130-3932	—
Cancer Institute of New Jersey	New Brunswick	New Jersey	08903	—
HemOnCare, P.C.	Brooklyn	New York	11235	—
North Shore University Hospital	Manhasset	New York	11030	—
State University of New York - Upstate Medical University	Syracuse	New York	13210	—
Albert Einstein Clinical Cancer Center	The Bronx	New York	10461	—
New York Medical College	Valhalla	New York	10595	—
West Clinic	Memphis	Tennessee	38120	—
Seattle Cancer Care Alliance	Seattle	Washington	98109	—
Medical College of Wisconsin	Milwaukee	Wisconsin	53226-3596	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00039156, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 24, 2008 · Synced Nov 12, 2026